Navigation Links
Drug design success propels efforts to fight HIV with a combination of 2 FDA-approved drugs
Date:8/30/2013

MINNEAPOLIS/ST. PAUL (08/30/2013) A University of Minnesota research team featuring researchers from the Institute for Molecular Virology, School of Dentistry and Center for Drug Design has developed a new delivery system for a combination of two FDA approved drugs that may serve as an effective treatment for the human immunodeficiency virus (HIV).

The discovery, which allows for a combination of decitabine and gemcitabine to be delivered in pill form, marks a major step forward in patient feasibility for the drugs, which previously had been available solely via injection or intravenous therapy (IV).

The study, coauthored by Christine Clouser, Ph.D., Laurent Bonnac, Ph.D., Louis Mansky, Ph.D., and Steven Patterson, Ph.D., can be found "online first" in the journal Antiviral Chemistry & Chemotherapy.

"If you have a condition that requires you to take a medication everyday, as many patients with HIV do, you wouldn't want to have to take that medication via daily injection," said Steven Patterson, Ph.D., professor at the Center for Drug Design at the University of Minnesota. "This finding is a big step in demonstrating this treatment could be taken as a pill, similar to other HIV drugs, and is suitable for eventual clinical translation."

University of Minnesota researchers first announced decitabine and gemcitabine could potentially combine to treat HIV in research published in August 2010. The drug combination was shown to work by lethal mutagenesis that could obliterate HIV by causing the virus to mutate to a point where it was no longer infectious. For some patients, HIV's ability to quickly mutate and evolve can result in drug resistance. For patients who have developed resistance to currently available HIV treatments, the decitabine-gemcitabine drug combination could prove an effective alternative and secondary line of defense.

In addition to a potentially effective treatment for humans with HIV, the combination also shows potential to treat cats with leukemia.

"There's still a lot of work that needs to be done to demonstrate the safety and efficacy of this drug combination before human clinical trials can begin," said Patterson. "But we're optimistic that we're moving forward."


'/>"/>

Contact: Miranda Taylor
tayl0551@umn.edu
612-626-2767
University of Minnesota Academic Health Center
Source:Eurekalert

Related biology news :

1. Keck award enables Carnegie Mellon and Stanford to dramatically expand crowdsourced RNA design
2. Report presents designs for study of cancer risks near US nuclear facilities
3. Research is ensuring stormwater systems are designed for the future
4. Scripps Florida scientist awarded $1.5 million to design therapeutics with new RNA approach
5. African scientist, designer partner to fashion anti-malaria garment that wards off bugs
6. Portable diagnostics designed to be shaken, not stirred
7. MIT-designed cooler preserves tuberculosis drugs, records doses
8. Progress in Osteoporosis re-launched with new design, now invites commentary
9. Faster, cheaper gas and liquid separation using custom designed and built mesoscopic structures
10. SACLA draws acclaim for unique XFEL design
11. A new type of data papers designed to publish online interactive keys identifying biodiversity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2019)... ... November 06, 2019 , ... NDA ... a senior pharmaceutical industry executive with expertise in clinical pharmacology and pharmacometrics and ... disease strategic data analytics, has joined the firm as an Expert Consultant. , ...
(Date:11/5/2019)... ... November 05, 2019 , ... Dr. Lauren ... restorative dentistry to Seattle, WA, including porcelain veneers , smile makeovers, dental ... the University of Washington, Dr. Kopp is passionate about serving her Seattle community ...
(Date:10/30/2019)... ... October 30, 2019 , ... The 2019 Precision Agriculture Technology ... participants will learn about precision agriculture tools used to enhance beef and dairy ... Participants will have the opportunity to visit Virginia Tech’s agricultural research center, Kentland ...
Breaking Biology News(10 mins):
(Date:11/27/2019)... , ... November 25, 2019 , ... ... has announced the company’s first robotic-assisted and navigated surgery in the UK. The ... (NHS) by acclaimed spine surgeons, Dr. Syed Aftab and Dr. Alexander Montgomery. The ...
(Date:11/22/2019)... ... November 21, 2019 , ... Lajollacooks4u is preparing for another ... events company already scheduled several of its popular cooking classes and team-building events, but ... , The company’s Holiday Parties have been a favorite for companies of all sizes ...
(Date:11/19/2019)... ... November 19, 2019 , ... Supercomputing Conference – Cirrascale ... for Autonomous Vehicle , Medical Imaging, and Natural Language Processing (NLP) workflows, ... Graphcore Poplar® software stack as part of its bare-metal cloud service offerings. In ...
(Date:11/12/2019)... BASEL, Switzerland (PRWEB) , ... ... ... leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that ... cancer immunotherapies, has adopted Genedata Biologics® to streamline their R&D ...
Breaking Biology Technology: